Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 3/2013

01-06-2013 | Hypertension and Obesity (E Reisin, Section Editor)

Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal?

Authors: Zohreh Soltani, Kashaf Rasheed, Daniel R. Kapusta, Efrain Reisin

Published in: Current Hypertension Reports | Issue 3/2013

Login to get access

Abstract

Elevated serum uric acid concentration is a common laboratory finding in subjects with metabolic syndrome/obesity, hypertension, kidney disease and cardiovascular events. Hyperuricemia has been attributed to hyperinsulinemia in metabolic syndrome and to decreased uric acid excretion in kidney dysfunction, and is not acknowledged as a main mediator of metabolic syndrome, renal disease, and cardiovascular disorder development. However, more recent investigations have altered this traditional view and shown, by providing compelling evidence, to support an independent link between hyperuricemia and increased risk of metabolic syndrome, diabetes, hypertension, kidney disease and cardiovascular disorders. However, despite these new findings, controversy regarding the exact role of uric acid in inducing these diseases remains to be unfolded. Furthermore, recent data suggest that the high-fructose diet in the United State, as a major cause of hyperuricemia, may be contributing to the metabolic syndrome/obesity epidemic, diabetes, hypertension, kidney disease and cardiovascular disorder. Our focus in this review is to discuss the available evidence supporting a role for uric acid in the development of metabolic syndrome, hypertension, renal disease, and cardiovascular disorder; and the potential pathophysiology mechanisms involved.
Literature
1.
Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34:78–84.PubMedCrossRef
2.
Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19:640–53.PubMedCrossRef
3.
Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973;1:449–51.PubMedCrossRef
4.
Johnson RJ et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.PubMedCrossRef
5.
Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131–9.PubMedCrossRef
6.
Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Ph. 2007;293:C584–96.CrossRef
7.
Corry DB et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269–75.PubMedCrossRef
8.
Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553–62.PubMedCrossRef
9.
Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Investig. 1977;60:999–1007.PubMedCrossRef
10.
11.
Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–80.PubMedCrossRef
12.
Nakanishi N et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523–30.PubMedCrossRef
13.
Sundstrom J et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33.PubMed
14.
15.
Bickel C et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:12–7.PubMedCrossRef
16.
Matsuura F et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabol Clin Exp. 1998;47:929–33.CrossRef
17.
Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25:1038–44.PubMedCrossRef
18.
Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008–11.PubMedCrossRef
19.
Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–7.PubMedCrossRef
20.
Muscelli E et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996;9:746–52.PubMedCrossRef
21.
Quinones Galvan A et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268:E1–5.PubMed
22.
Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabol Clin Exp. 2008;57:845–52.CrossRef
23.
Ryu S et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol. 2007;17:245–52.PubMedCrossRef
24.
Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31:361–2.PubMedCrossRef
25.
Niskanen L et al. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care. 2006;29:709–11.PubMedCrossRef
26.
27.
28.
Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25:210–6.PubMedCrossRef
29.
•• Osgood K, Krakoff J, Thearle M. Serum Uric Acid Predicts Both Current and Future Components of the Metabolic Syndrome. Metab Syndr Relat Disord. 2013. doi:10.​1089/​met.​2012.​0151. This study demonstrates that not only did uric acid associate with concomitant insulin action, lipids, and blood pressure, also predicts future declines in insulin action and T2DM.
30.
31.
Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev. 2005;63:133–57.PubMedCrossRef
32.
Teff KL et al. Endocrine and Metabolic Effects of Consuming Fructose- and Glucose-Sweetened Beverages with Meals in Obese Men and Women: Influence of Insulin Resistance on Plasma Triglyceride Responses. J Clin Endocr Metab. 2009;94:1562–9.PubMedCrossRef
33.
34.
Sanchez-Lozada LG et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Ren Physiol. 2008;294:F710–8.CrossRef
35.
36.
Mercuro G et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932–5.PubMedCrossRef
37.
Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221–6.PubMedCrossRef
38.
Kanbay M et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clinical J Am Soc Nephrol. 2011;6:1887–94.CrossRef
39.
Yelken B et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol. 2012;77:275–82.PubMed
40.
Ho WJ et al. Association between endothelial dysfunction and hyperuricaemia. Rheumatology. 2010;49:1929–34.PubMedCrossRef
41.
Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. American journal of physiology. J Cell Physiol. 2007;293:C584–596.CrossRef
42.
Furukawa S et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Investig. 2004;114:1752–61.PubMed
43.
Jacob S. Patient with beer belly or hypertension. Check for a metabolic syndrome! MMW Fortschr Med. 2005;147:45.PubMed
44.
Reungjui S et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol. 2007;18:2724–31.PubMedCrossRef
45.
Kodama S et al. Association Between Serum Uric Acid and Development of Type 2 Diabetes. Diabetes Care. 2009;32:1737–42.PubMedCrossRef
46.
Alper AB et al. Childhood uric acid predicts adult blood pressure - The Bogalusa Heart Study. Hypertension. 2005;45:34–8.PubMed
47.
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. New Eng J Med. 1966;275:457–64.PubMedCrossRef
48.
Turak O et al. Serum uric Acid, inflammation, and nondipping circadian pattern in essential hypertension. J Clin Hypertens. 2013;15:7–13.CrossRef
49.
Lim KH, Friedman SA, Ecker JL, Kao L, Kilpatrick SJ. The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 1998;178:1067–71.PubMedCrossRef
50.
Mazzali M et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101–6.PubMedCrossRef
51.
Nakagawa T et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23:2–7.PubMedCrossRef
52.
•• Kanbay M et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013. doi:10.​1136/​heartjnl-2012-302535. This very good review article summarizes the emerging roles of uric acid in the pathogenesis of kidney disease,metabolic syndrome and diabetes and cardiovascular disease. All potential pathogenesis such as induction of oxidative stress, inflammation, endothelial dysfunction and activation of the rennin angiotensin aldosterone system were reviewed.
53.
Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247–52.PubMedCrossRef
54.
Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension—A randomized trial. JAMA. 2008;300:924–32.PubMedCrossRef
55.
Gibson TJ. Hypertension, its treatment, hyperuricaemia and gout. Curr Opin Rheumatol. 2013;25:217–22.PubMedCrossRef
56.
57.
Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis risk in communities (ARIC) study. Ann Epidemiol. 2000;10:136–43.PubMedCrossRef
58.
Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001;87:1411–4.PubMedCrossRef
59.
Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998;29:635–9.PubMedCrossRef
60.
Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB. Uric acid is a risk factor for myocardial infarction and stroke - The Rotterdam Study. Stroke. 2006;37:1503–7.PubMedCrossRef
61.
Okura T et al. Elevated Serum Uric Acid is an Independent Predictor for Cardiovascular Events in Patients With Severe Coronary Artery Stenosis - Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J. 2009;73:885–91.PubMedCrossRef
62.
Madsen TE et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol. 2005;25:45–9.PubMedCrossRef
63.
Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61:225–32.PubMedCrossRef
64.
Ndrepepa G et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012;109:1260–5.PubMedCrossRef
65.
Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2:e76.PubMedCrossRef
66.
Kim SY et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62:170–80.
67.
Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999;34:144–50.PubMedCrossRef
68.
Anker SD et al. Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging. Circulation. 2003;107:1991–7.PubMedCrossRef
69.
Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin. 2004;20:369–79.PubMedCrossRef
70.
Cappola TP et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407–11.PubMedCrossRef
71.
George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508–16.PubMedCrossRef
72.
Dahlof B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRef
73.
Hoieggen A et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041–9.PubMedCrossRef
74.
Kim SY et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885–92.PubMedCrossRef
75.
Newman EJ, Rahman FS, Lees KR, Weir CJ, Walters MR. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metabol Res Rev. 2006;22:79–82.CrossRef
76.
Chamorro A et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke. 2002;33:1048–52.PubMedCrossRef
77.
Leyva F et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18:858–65.PubMedCrossRef
78.
Haig A. Uric acid as a factor in the causation of disease. London: J & A Churchill; 1897.
79.
Berger L, Yu TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605–13.PubMedCrossRef
80.
Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169:342–50.PubMedCrossRef
81.
Obermayr RP et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2008.CrossRef
82.
• Iseki K et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–7. This study with the large number of subjects (6,403) demonstrated that serum uric acid was a significant positive correlate of developing renal dysfunction in Japanese population.
83.
84.
Liu Y et al. The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine. Clinics. 2013;68:19–25.PubMedCrossRef
85.
• Helal I et al. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2012. doi:10.​1093/​ndt/​gfs417.
86.
Kotsis V. S. S., Bouldin M, Low A, Toumanidis S, Zakopoulos N. Impact of obesity on 24-h ambulatory blood pressure and hypertension. Hypertension. 2005;45:602–7.PubMedCrossRef
87.
Kang DH et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888–97.PubMedCrossRef
88.
Mazzali M et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. AmJ Physiol Ren Physiol. 2002;282:F991–997.
89.
Kim SM et al. Reducing Serum Uric Acid Attenuates TGF-beta(1)-Induced Profibrogenic Progression in Type 2 Diabetic Nephropathy. Nephron Exp Nephrol. 2013;121:e108–20.
90.
• Terawaki H et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study. Clinical and Exp Nephrol. 2012. doi:10.​1007/​s10157-012-0742-z. This study shows that the use of allopurinol in hypertensive patients withkidney dysfunction seems to be beneficial in preventing cardiovascular morbidity and all-cause mortality.
91.
• Miao Y et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58:2–7. This study supports that renoprotective effect of losrtan could partially be due to reduction of serum uric acid level. Losartan lowers uric acid levels compared with placebo treatment in patients with type 2 diabetes mellitus and nephropathy. These findings suggest that uric acid may be a modifiable risk factor for kidney disease.
92.
Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J Nutr. 2009;139:1228S–35S.PubMedCrossRef
93.
Johnson RJ et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86:899–906.PubMed
94.
Schulze MB et al. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 2004;292:927–34.PubMedCrossRef
95.
Gersch MS et al. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Ren Physiol. 2007;293:F1256–1261.CrossRef
96.
Shoham DA et al. Sugary soda consumption and albuminuria: results from the National Health and Nutrition Examination Survey, 1999–2004. PLoS One. 2008;3:e3431.PubMedCrossRef
97.
• Brymora A et al. Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol Dial Transplan. 2012;27:608–12. This clinical study shows the importance of low fructose diet in reduction of inflammation in patients with chronic kidney disease.
98.
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.PubMedCrossRef
99.
Perez-Pozo SE et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes. 2010;34:454–61.CrossRef
Metadata
Title
Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal?
Authors
Zohreh Soltani
Kashaf Rasheed
Daniel R. Kapusta
Efrain Reisin
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 3/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-013-0344-5

Other articles of this Issue 3/2013

Current Hypertension Reports 3/2013 Go to the issue

Hypertension and Obesity (E Reisin, Section Editor)

Guidelines Updates in the Treatment of Obesity or Metabolic Syndrome and Hypertension

Hypertension and Obesity (E Reisin, Section Editor)

Pharmacologic Treatment Options for Obesity: What Is Old Is New Again

Therapeutic Trials (G Mancia, Section Editor)

Role of Ambulatory Blood Pressure Monitoring in Resistant Hypertension

Hypertension and Obesity (E Reisin, Section Editor)

Exercise Training and Cardiometabolic Diseases: Focus on the Vascular System

Invited Commentary

Obstructive Sleep Apnea and Hypertension: Is the Primary Link Simply Volume Overload?

Blood Pressure Monitoring and Management (J Redon, Section Editor)

Ambulatory Blood Pressure Monitoring in the Prediction and Prevention of Coronary Heart Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits